on CureVac (NASDAQ:CVAC)
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company focusing on mRNA-based medicines, announced the appointment of Dr. Mehdi Shahidi to its Supervisory Board. He replaces Ralf Clemens, who served from March 2016 to September 2023. Dr. Shahidi's expertise aligns with CureVac's focus on innovative technologies and mRNA-based cancer vaccines.
Dr. Shahidi, currently the CEO of Petalion Therapeutics and a Venture Partner at Medicxi, brings valuable experience in oncology and drug development. His prior roles include Senior Vice President at Boehringer Ingelheim, where he oversaw multiple drug approvals and clinical advancements.
His appointment begins in September 2024 at CureVac SE, with another appointment for CureVac N.V. to be considered at the next Annual General Meeting in June 2025. Dr. Shahidi looks forward to contributing to CureVac's pioneering work in mRNA technologies.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CureVac news